| Company* | University/ | Type Of Agreement | Product Area | Details (Date) |
| | ||||
| Advancis Pharmaceu- | The Institute for Genomic Research | Research and license agreement | Comparison of Advancis' Pulsys-delivered antibiotics on microbial expression profiles with those of microbes exposed to traditional dosing schemes | The goal is to evaluate the effect of amoxicillin on Streptococcus pneumoniae expression profiles (9/25) |
| Agilent Technol- | Royal Netherlands Academy of Science institutes | Technology access agreement | DNA microarrays and a microarray scanner | The technology will be used by the Netherlands Brain Research Institute for the study of neurological diseases and peripheral and central nervous system regeneration, and the Netherlands Ophthalmic Research Institute, which will research age-related macular degeneration, glaucoma and retinitis pigmentosa (10/1) |
| Antisoma plc | National Institutes | Licensing agreement | Enzyme, recombinant cytotoxic RNase | Antisoma acquired exclusive worldwide rights to RNase, in combination with monoclonal antibodies that target PEM and CEA - protein targets found on certain cancer cells (9/10) |
| Atrix Lab- | Tulane University Health Sciences Center | Exercised option licensing agreement | Human growth hormone releasing peptide-1 | Atrix will develop the compound using its sustained-release Atrigel delivery technology (9/10) |
| Avigen | Lawrence Berkeley Laboratory | Exclusive worldwide license | Interest in a patent covering a potential Parkinson's disease therapy | Avigen has exclusive rights to a family of U.S. and European patent applications; Avigen also has the right to sublicense any eventual patents to third parties (8/27) |
| Biophage | Public Works and Government Services Canada | Contracts | Immune defense mechanisms to fight anthrax and plague infections | The contracts are worth C$0.58M (US$0.37M) and are part of a bigger agreement the company has with the Department of National Defense and the Defense Research Establishment Suffield (10/16) |
| BresaGen | Monash University | Collaboration | New stem cell research facility | BresaGen will team up with the university's research groups to exploit applications of human embryonic stem cell technology; the new facility is being funded by the Australian government (8/24) |
| Celera | The SNP | Contract agreement | Data for a genome-wide SNP-based linkage map for genetic analysis | The map will consist of 2,000 SNPs selected from the consortium's database that will be validated by Celera using Applied Biosystems' TaqMan reagent system (8/28) |
| Charles | Medical College of Wisconsin in Milwaukee | Distribution agreement | Consomic rat models | The models are designed to allow researchers to study the specific function of particular genes that contribute to common multigenic human diseases of the heart, lung and blood (9/27) |
| Common- | Unnamed | Contract | To perform detailed DNA sequence analyses of particular organisms for strain differentiation | The contract is expected to generate nearly $800,000 over the next five years, with $200,000 anticipated in the first year of the contract (9/26) |
| Entomed SA | Shanghai Institute | Collaboration | Insect extracts | Entomed intends to develop new drugs using the extracts for a range of therapeutic areas (10/15) |
| Esperion | University of Michigan | License agreement | Paraoxonase technology | Exclusive rights agreement for Esperion to develop the technology; Esperion will pay the university license fees, maintenance fees, milestone payments and royalties (10/1) |
| Galapagos | Flanders Interuniversity Institute of Biotechnology (VIB) | Collaboration | Drug targets against Alzheimer's disease | Collaboration is to identify and validate the drug targets; genes identified that modulate gamma-secretase activity will be further validated as potential drugs or targets by Galapagos and a group from VIB (8/30) |
| Genetastix | Development Center for Biotechnology (Taiwan) | Access agreement | Genetastix's HuMyTech platform | DCB will use the platform to generate fully human monoclonal antibodies against entrovirus type 71; Genetastix will receive research and development payments, milestone payments and royalties (10/10) |
| Hybrigenics | Institut | Exclusive collaboration | Functional proteomics | Agreement is for infectious diseases and is an extension to a 1998 agreement (10/15) |
| Integrative | University | Joint research and licensing agreement | To functionally map certain pathogenic bacterial proteomes | The effort will receive more than $9M in funding from the Ontario Research and Development Challenge Fund (10/1) |
| InterCell | Centre for Applied Microbiology and Research | Licensing agreement | Antigen discovery technology | The technology will help develop vaccines against a range of infectious diseases; hepatitis C will be the first target (9/26**) |
| Introgen | M.D. Anderson Cancer Center | Licensing agreement | Sequenced genes that play roles in suppressing and preventing development of lung and other cancers | The technologies have been added to Introgen's broad exclusive license agreement with M.D. Anderson (10/11) |
| LigoCyte | National Institute | Cooperative research and development agreement | Rabies DNA vaccine | The vaccine is targeted to mucosal tissues in the nose and mouth; LigoCyte will provide its M-cell targeting technology (9/18) |
| MediGene | Children's Hospital | Expanded licensing agreement | Herpes simplex virus-based amplicon technology | The exclusive worldwide license entitles MediGene to use the HSV amplicon technology for all prophylactic and therapeutic applications in humans as well as for commercial research purposes (9/6) |
| MediGene | Memorial Sloan-Kettering Cancer Center | Exclusive option agreement | Intellectual property for cancer treatment | The agreement is for property regarding the use of chemotherapy in combination with MediGene's proprietary oncolytic herpes simplex viruses to treat cancer (8/22**) |
| Medivir AB | Michael Curtis at Barts, the London School of Medicine and Dentistry, Queen Mary and the University of London | Collaboration | Antibiotics | The project aims to use a novel and highly focused applied genomics approach to develop protease inhibitors as specific antimicrobials against M. tuberculosis, H. pylori, P. aeruginosa and S. aureus (8/27) |
| Modex | University | Exclusive license agreement | Technology covering a family of small-peptide molecules | The molecules can be used to modulate the location and number of melanocytes in the epidermis (10/1) |
| NaPro | University of Alabama at Birmingham | Exclusive worldwide licensing agreement | A broad technology relating to any receptor ligand peptides conjugated to any taxane | The technology includes paclitaxel (9/11) |
| Ocean | University of Linkoping | In-licensing agreement | Three compounds in the anti-inflammatory field | The agreement is with a scientist at the university for the compounds with new mechanisms of action in the anti-inflammatory field; the first focus will be in asthma (9/10) |
| Orchid | Oklahoma Medical Research Foundation | Genotyping service agreement | SNP scoring on samples provided by OMRF | The collaboration is focused on the analysis of SNPs related to autoimmune diseases (9/25) |
| Oxigene Inc. | National Eye Institute | Materials- cooperative research and development agreement | To study the effects of Combretastin on an animal model of proliferative diabetic retinopathy | Oxigene retains all rights for non-systemic uses of CA4P (9/26) |
| Peregrine | University of Texas | Exclusive worldwide licenses | Cancer compounds | Peregrine licensed technology that uses antibodies that target phosphatidylserine on the surface of tumor endothelial cells, and an antibody, 2C3, that neutralizes vascular endothelial growth factor (8/29) |
| Phylos | Lawrence Livermore National Laboratory | Development partnership | High-throughput methods for protein production to create research reagents and microarrays | The reagents and microarrays may be used to design new drugs or diagnostic tools (10/11) |
| Prana | Massachusetts General Hospital | Cross- relationship agreement | Pramipexole | Prana will pay for a portion of Alzheimer's disease research; Prana receives an exclusive license to the patent application for use of pramipexole, which is being tested in patients with Parkinson's disease (8/31) |
| Pyro- | University of Geneva | Sponsored research agreement | Analyze genes and develop diagnostic tests for Down's syndrome | The parties will do the work using Pyrosequencing technology (8/29) |
| Pyro- | Stuart C. Clarke | Research collaboration | To investigate applications for Pyrosequencing in infectious bacterium Neisseria meningitidis | The bacterium is the leading cause of meningococcus worldwide (9/26) |
| RegeneRx | University of Texas SouthWestern Medical Center | Materials transfer agreement | Thymosin beta 4 in the cardiac field | The company will provide quantities of T_4, as well as expertise and data, to the university; the company may use any invention or discovery for internal research purposes and retains an option to negotiate an exclusive, worldwide, royalty-bearing license for commercialization (8/30) |
| Revotar | Fraunhofer | Licensing agreement | Macrophage migration inhibitory factor | Revotar expects the collaboration to lead to the identification of a lead clinical candidate next year (10/8) |
| SafeScience | Massachusetts Institute of Technology | Sponsored research program | GBC-590 | The program will focus on GBC-590 and identification of other compounds with promising biochemical and pharmaceutical activity (9/19) |
| Samaritan | Georgetown University | Exclusive worldwide license | Cholesterol-recognition amino-acid sequence | Georgetown granted Samaritan an exclusive worldwide license to commercialize the sequence (9/11) |
| Synthon | Michigan State University | Collaboration | Biochemistry technology | Under the new, four-year expanded partnership deal, Synthon will receive exclusive worldwide rights to the technology; Synthon will provide $1.1M to support research efforts, plus royalties (9/6) |
| Tranzyme | Cystic Fibrosis Foundation Therapeutics Inc. (a non-profit affiliate of the Cystic Fibrosis Foundation) | Partnership | Novel cell lines to be used for cystic fibrosis drug discovery | Resulting cell lines will be available to the cystic fibrosis research community; Tranzyme will receive research and development support; they will share future revenue from these cell lines (10/9) |
| Tranzyme | University of Utah | Collaboration | Bioinformatics and applied genomics | The parties will jointly develop gene libraries using the university's sequence database (10/17) |
| Virax | Michael Brown of Royal Adelaide Hospital's Cancer Center | Collaboration | Immune-based therapy to treat prostate cancer | The vaccine to be developed will use Virax's platform technology, Co-X-Gene, in fowlpox virus vector (8/21) |
| | ||||
Notes: | ||||
This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers. | ||||
| * Denotes privately held company. |
||||
| ** Denotes the date the item ran in BioWorld International. |
||||
| Unless otherwise noted, shares are traded on the Nasdaq exchange. |
||||
| AMEX = American Stock Exchange; ASX = Australia Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange |
||||
